Welcome : Guest

GenVec, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about GenVec, Inc., which is principally involved in Clinical-Stage Biopharmaceuticals Business. Illustrated with 86 tables, the report showcases the company's recent sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-35240
Price: $3500
Company Type: Public
Pages: 90
Date: November 2016
Market Data Tables: 86

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: GenVec, Inc.'s Revenues by Category (2015) in Percentage for Hearing Program, Foot and Mouth Disease Program, Malaria Program, and Other Strategic Collaborations and Research Grants......2
Table 2: GenVec, Inc.’s Sales by Business Segment (2014) in Percentage for Hearing Program, Foot and Mouth Disease Program, and Malaria Program......3
Biopharmaceuticals......7
Table 3: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......7
Vaccines......8
Table 4: Vaccines Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Adult Prophylactic Vaccines (USD 8.5bn), Pediatric Vaccines (USD 16.7bn) and Others......8
Foot and Mouth Disease Vaccines......9
Table 5: Animal Health Market by Therapeutic Class Worldwide (2015) - Percentage Share Breakdown by Value for Antibiotics and Therapeutic, Antiparasitic, Foot and Mouth Disease Vaccine, Supplements and Others......9
Infectious Disease Drugs......10
Table 6: Infectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......10
Table 7: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......11
Cancer Drugs......12
Table 8: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......12
Table 9: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......13
Cancer Market......14
Table 10: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......14
Table 11: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......15
Table 12: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......16
Table 13: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......17
Table 14: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......18
Table 15: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......19
Table 16: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......20
Table 17: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......21
Cancer Patients......22
Table 18: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......22
Table 19: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......23
Table 20: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......24
Table 21: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......25
Table 22: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......26
Table 23: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......27
Table 24: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......28
Table 25: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......29
Table 26: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......30
Table 27: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......31
Table 28: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......32
Table 29: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......33
Table 30: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......34
Table 31: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......35
Table 32: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......36
Table 33: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......37
Table 34: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......38
Table 35: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......39
Table 36: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......40
Table 37: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......41
Table 38: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......42
Cervical Cancer......43
Table 39: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......43
Table 40: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......44
Hematological Cancer......45
Table 41: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......45
Skin Cancer......46
Table 42: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......46
Cancer-Associated Mucositis......47
Table 43: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......47
Chronic Myelogenous Leukemia (CML)......48
Table 44: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......48
Multiple Myeloma......49
Table 45: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......49
Table 46: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......50
Cell Therapy......51
Table 47: Therapeutic Development Market by Product Worldwide (2015) - Percentage Share Breakdown by Volume for Cell Therapy, Monoclonal Antibodies, Vaccines and Others......51
Table 48: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......52
Immunotherapy......53
Table 49: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......53
Table 50: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......54
Gene Therapy......55
Table 51: Gene Therapy Clinical Trials Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Phase I, n=1183, Phase I/II, n=384, Phase II, n=330, Phase II/III, n=20 and Phase III, n=74......55
Malaria Therapeutics......56
Table 52: Anti-Malaria Treatment Market by Therapy in Ghana (2015) - Percentage Share Breakdown by Volume for Artemisinin-based Combination Therapies that are not QAACTs, Artemisinin Monotherapy, Non-Artemisinin Therapy and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......56
Table 53: Anti-Malaria Treatment Market by Therapy in Kenya (2015) - Percentage Share Breakdown by Volume for Artemisinin-based Combination Therapies that are not QAACTs, Artemisinin Monotherapy, Non-Artemisinin Therapy and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......57
Table 54: Anti-Malaria Treatment Market by Therapy in Madagascar (2015) - Percentage Share Breakdown by Volume for Artemisinin-based Combination Therapies that are not QAACTs, Non-Artemisinin Therapy and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......58
Table 55: Anti-Malaria Treatment Market by Therapy in Niger (2015) - Percentage Share Breakdown by Volume for Quality-assured Artemisinin-based Combination Therapies (QAACTs), Artemisinin-based Combination Therapies that are not QAACTs and Non-Artemisinin Therapy......59
Table 56: Anti-Malaria Treatment Market by Therapy in Nigeria (2015) - Percentage Share Breakdown by Volume for Artemisinin Monotherapy, Artemisinin-based Combination Therapies that are not QAACTs, Non-Artemisinin Therapy and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......60
Table 57: Anti-Malaria Treatment Market by Therapy in Tanzania (2015) - Percentage Share Breakdown by Volume for Artemisinin-based Combination Therapies that are not QAACTs, Non-Artemisinin Therapy and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......61
Table 58: Anti-Malaria Treatment Market by Therapy in Uganda (2015) - Percentage Share Breakdown by Volume for Artemisinin-based Combination Therapies that are not QAACTs, Non-Artemisinin Therapy, and Quality-assured Artemisinin-based Combination Therapies (QAACTs)......62
Table 59: Anti-Malaria Treatment Market by Therapy in Zanzibar (2015) - Percentage Share Breakdown by Volume for Quality-assured Artemisinin-based Combination Therapies (QAACTs), Artemisinin-based Combination Therapies that are not QAACTs, Artemisinin Monotherapy and Non-Artemisinin Therapy......63
Table 60: Population Suspected with Malarial Infection Worldwide (2015) - Percentage Share Breakdown by Volume for Population Exposed to Infection, Population Suspected of Infection, Uninfected Population and Others......64
Biopharmaceuticals......65
Table 61: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......65
Table 62: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......66
Vaccines......67
Table 63: Market Shares of Leading Vaccine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for GlaxoSmithKline Plc (GSK), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., and Others......67
Diphtheria and Tetanus Vaccines......68
Table 64: Market Shares of Leading Diphtheria and Tetanus Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Infanrix), and Others......68
Hepatitis A Vaccines......69
Table 65: Market Shares of Leading Hepatitis A Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Havrix), and Others......69
Hepatitis B (Recombinant) Vaccines......70
Table 66: Market Shares of Leading Hepatitis B (Recombinant) Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for Engerix (GlaxoSmithKline Plc), and Others......70
Hepatitis A and Typhoid Polysaccharide Vaccines......71
Table 67: Market Shares of Leading Hepatitis A and Typhoid Polysaccharide Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Hepatyrix), and Others......71
Human Papillomavirus Vaccines......72
Table 68: Market Shares of Leading Human Papillomavirus Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Cervarix), and Others......72
Human Rotavirus Vaccines......73
Table 69: Market Shares of Leading Human Rotavirus Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Rotarix), and Others......73
Influenza Vaccines......74
Table 70: Market Shares of Leading Influenza Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Fluarix), and Others......74
Measles, Mumps and Rubella Vaccines......75
Table 71: Market Shares of Leading Measles, Mumps and Rubella Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Priorix), and Others......75
Tetanus Toxoid, reduced Diphthera Vaccines......76
Table 72: Market Shares of Leading Tetanus Toxoid, reduced Diphthera Vaccine Manufacturers in India (2014) - Percentage Breakdown by Value Sales for GlaxoSmithKline Plc (Boostrix), and Others......76
Typhoid Vaccines......77
Table 73: Market Shares of Leading Typhoid Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Typherix), and Others......77
Varilrix Vaccines......78
Table 74: Market Shares of Leading Varilrix Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Varilrix), and Others......78
Infectious Disease Drugs......79
Table 75: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......79
Cancer Drugs......80
Table 76: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......80
Table 77: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......81
Table 78: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......82
Table 79: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......83
Table 80: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......84
Breast Cancer Drugs......85
Table 81: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......85
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......86
Table 82: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......86
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......87
Table 83: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......87
Table 84: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......88
Malaria Therapeutics......89
Table 85: Market Shares of Leading Affordable Medicines Facility Malaria (AMFm) Manufacturers by Value Sales Worldwide (2015) - Percentage Breakdown for Ajanta Pharma Limited, Cipla Limited, Ipca Laboratories, Novartis AG, Strides Arcolab Limited, and Others......89
Table 86: GenVec, Inc.’s Revenues by Category Worldwide (2013) in Percentage for Hearing Program, Foot and Mouth Disease Program, Vaccine Research Center, Malaria Program and Other Strategic Alliances and Research Grants......90